P262 Tiotropium Safety And Performance In Respimat(R) (tiospir ): Safety And Efficacy In Patients With Tiotropium Handihaler(R) Use At Baseline

Abstract

Introduction The TIOSPIR™ trial showed that tiotropium Respimat® and HandiHaler® have similar safety and exacerbation efficacy profiles in patients with chronic obstructive pulmonary disease (COPD). We present here results for patients from the United States (US) using tiotropium HandiHaler® at baseline. Methods TIOSPIR™ (n = 17,135), a 2-3 year, randomised, double-blind, parallel-group, event-driven trial, compared safety and efficacy of once-daily tiotropium Respimat® 5 and 2.5 μg with once-daily HandiHaler® 18 μg in patients with COPD. Primary endpoints were time to death and time to first COPD exacerbation. Safety, including cardiovascular safety, was assessed. Tiotropium Respimat® was unavailable in the US (baseline tiotropium HandiHaler® use only), therefore this subgroup was analysed. Results Overall, 1779 patients from TIOSPIR™ treated with tiotropium HandiHaler® 18 μg at baseline in the US were randomised and treated (n = 572, n = 602 and n = 605 for tiotropium Respimat® 2.5 and 5 μg and HandiHaler® 18 μg). A numerically lower time to death was observed for patients within the Respimat® groups versus HandiHaler® (vital status follow up: Respimat® 5 μg: hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.53-1.12; Respimat® 2.5 μg: HR, 0.76; 95% CI, 0.52-1.12). Risk of major adverse cardiovascular event (MACE) and fatal MACE was numerically lower for the Respimat® groups versus HandiHaler® (MACE: Respimat® 5 μg: HR, 0.69; 95% CI, 0.41-1.18; Respimat® 2.5 μg: HR, 0.83; 95% CI, 0.50-1.39; fatal MACE: HR, 0.60; 95% CI, 0.26-1.37; Respimat® 2.5 μg: HR, 0.42; 95% CI, 0.16-1.09). Overall incidence of a fatal event (on-treatment) was lower in the Respimat® groups versus HandiHaler® (Respimat® 5 μg: HR, 0.60; 95% CI, 0.39-0.92; Respimat® 2.5 μg: HR, 0.67; 95% CI, 0.44-1.02). Time to first exacerbation was similar across groups (Respimat® 5 μg versus HandiHaler®: HR, 0.94; 95% CI, 0.82-1.08). Conclusions Patients treated with tiotropium HandiHaler® 18 μg at baseline, and who were randomised and subsequently received tiotropium Respimat® 2.5 or 5 μg, had a similar risk of exacerbation as patients who continued to be treated with tiotropium HandiHaler® 18 μg. In this subgroup of patients, all-cause mortality was similar between tiotropium Respimat® and HandiHaler® 18 μg.